sr141716 has been researched along with neurotensin in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alonso, R; Fournier, M; Labie, C; Le Fur, G; Soubrié, P; Souilhac, J; Steinberg, R; Voutsinos, B | 1 |
| Arvanitis, L; Bauer, D; Meltzer, HY; Rein, W | 1 |
1 trial(s) available for sr141716 and neurotensin
| Article | Year |
|---|---|
Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Cannabinoids; Double-Blind Method; Drugs, Investigational; Female; Haloperidol; Humans; Male; Middle Aged; Neurotensin; Peptide Fragments; Piperidines; Placebos; Psychotic Disorders; Pyrazoles; Pyrrolidonecarboxylic Acid; Receptors, Neurokinin-3; Research Design; Rimonabant; Schizophrenia; Serotonin 5-HT2 Receptor Antagonists; Treatment Outcome | 2004 |
1 other study(ies) available for sr141716 and neurotensin
| Article | Year |
|---|---|
Blockade of cannabinoid receptors by SR141716 selectively increases Fos expression in rat mesocorticolimbic areas via reduced dopamine D2 function.
Topics: Animals; Brain; Cannabinoids; Dopamine; Gene Expression Regulation; Genes, fos; Limbic System; Male; Microdialysis; Neurotensin; Piperidines; Prefrontal Cortex; Pyrazoles; Rats; Rats, Sprague-Dawley; Receptors, Cannabinoid; Receptors, Dopamine D2; Receptors, Drug; Rimonabant | 1999 |